Last reviewed · How we verify
NCT05460195
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
Phase 2 trial testing sintilimab combined with anlotinib in Non-small Cell Lung Cancer in 42 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 1 January 2022 |
| Primary completion | 30 September 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- sintilimab combined with anlotinib — full drug profile →
- sintilimab monotherapy — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Minimal Residual Disease — all drugs for Minimal Residual Disease →
- Immunotherapy — all drugs for Immunotherapy →
- Anti-angiogenesis — all drugs for Anti-angiogenesis →
Sponsor
Shanghai Chest Hospital
Who can join
Adults 18 to 75, any sex, with Non-small Cell Lung Cancer or Minimal Residual Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on evaluating minimal residual disease.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelial cells in tumor microenvironment: insights and perspectives.
Leone P, Malerba E, Susca N, Favoino E, et al · · 2024 · cited 90× · PMID 38426109 · DOI 10.3389/fimmu.2024.1367875 -
Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.
Sandbank E, Eckerling A, Margalit A, Sorski L, et al · · 2023 · cited 10× · PMID 37623021 · DOI 10.3390/curroncol30080540 -
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.
Parisi C, Tagliamento M, Belcaid L, Aldea M, et al · · 2023 · cited 8× · PMID 40027283 · DOI 10.1016/j.jlb.2023.100007 -
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited.
Denis MG, Herbreteau G, Pons-Tostivint E. · · 2023 · cited 5× · PMID 36895928 · DOI 10.21037/tlcr-22-899 -
Drug development and evidence for lung cancer targeted therapy in Eastern Asia.
Maggie Liu SY, Jin ZY, Deng JY, Zhong SM, et al · · 2024 · cited 2× · PMID 39381018 · DOI 10.1016/j.lanwpc.2024.101090 -
Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches.
Zheng T, Yu X, Yu C, Xu W, et al · · 2025 · PMID 41444687 · DOI 10.1186/s40364-025-00883-y -
Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer.
Dhillon P, Du S, Cheng H. · · 2025 · PMID 41154383 · DOI 10.3390/cancers17203327
Verify or expand the search:
- PubMed search for NCT05460195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sintilimab combined with anlotinib
Trials testing the same drug.
- NCT04691388 — A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor · Phase 2 · completed
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05460195 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 15 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05460195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing